EP1429801A1 - Neuropiline comme nouvelle cible therapeutique pour la modulation de reponses immunitaires - Google Patents

Neuropiline comme nouvelle cible therapeutique pour la modulation de reponses immunitaires

Info

Publication number
EP1429801A1
EP1429801A1 EP02779818A EP02779818A EP1429801A1 EP 1429801 A1 EP1429801 A1 EP 1429801A1 EP 02779818 A EP02779818 A EP 02779818A EP 02779818 A EP02779818 A EP 02779818A EP 1429801 A1 EP1429801 A1 EP 1429801A1
Authority
EP
European Patent Office
Prior art keywords
neuropilin
cells
cell
expression
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02779818A
Other languages
German (de)
English (en)
Inventor
Rafaele Tordjman
Yves Lepelletier
Paul-Henri Romeo
Olivier Hermine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to EP02779818A priority Critical patent/EP1429801A1/fr
Publication of EP1429801A1 publication Critical patent/EP1429801A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • reaction mixture comprising : DCs or more generally Antigen Presenting Cells which can be primary cells or cell lines, at least one potential binding modulator to be tested and, NKT cells, and (ii) determining whether the interaction of APCs, e.g. DCs, with NKT cells is increased or decreased in comparison to an assay which lacks the potential binding modulator.
  • APCs e.g. DCs
  • inhibition of neuropilin activity is achieved by inhibiting the transcription of neuropilin.
  • B NP-1 is required for DC-induced allogenic T cell proliferation.
  • DC and resting T cells were first pre-incubated with human IgG to block Fc receptors on DC.
  • DC were then pre-incubated with non blocking NP-1 antibody (H286), blocking NP-1 antibody (28. II), blocking CD58 antibody (CD58) or a combination of blocking CD58 and NP-1 antibodies (CD58 + 28.ll).
  • the allogenic resting J cells were then added to these pre-treated DC.
  • the allogenic resting T cells were pre-incubated with non blocking NP-1 antibody (H286) or blocking NP-1 antibody (28. II) and then co-cultured with DC.
  • the control represented DC and T cells without any antibody pre-incubation.
  • FIG. 6 shows the expression of intracytoplasmic Sema3A during PHA and IL-2 induced human T cell activation.
  • T cells were collected at the indicated time, fixed, permeabilized and stained with anti-Sema3A antibody. The mean fluorescence intensity obtained as a function of time is shown.
  • Human monocytes and resting T cells were isolated from peripheral blood mononuclear cells of healthy volunteers by means of a monocyte and a pan T cells isolation kits (Miltenyi Biotec, Bergisch Gladbach, Germany) as described in Geissmann, F. et al. (1998). The purity of monocytes, evaluated by CD14 staining, and of resting T cells, evaluated by CD5 and CD19 staining, was always greater than 95%o. Immature DC were obtained from monocytes as described in Geissmann, F. et al. (1998). Culture of human marrow adherent cells was performed as described in Tordjman R. et al. (1999).
  • Primer sequences of human NP-1 , NP-2, the soluble NP-1 isoforms S1 1 and S12 and the soluble NP-2 isoform S9 are the following: forward primers 5' ACG ATG
  • DC or resting T cells were first blocked with human IgG (10mg/ml) and preincubated with/without the anti-NP-1 blocking rabbit antibody IgG purified (10 ⁇ g/ml) (Geijtenbeek T.B.H. et al., 2000 a) for 30 min at 4°C.
  • the blocking NP-1 antibody 28. II (against amino acids 265 to 857) was used as previously described at 10 ⁇ g/ml and the control used was a non blocking NP-1 antibody, H286 (against amino-acids 570 to 855) (Santacruz). These two antibodies recognized extracellular epitopes.
  • NP-1 is also involved in the innate immunity because of its expression on DC and NKT cells and by NP-1 role on this interaction modulating the cytokine secretion necessary for this immune response.
  • Neuropilin is a receptor for the axonal chemorepellent semaphorin III. Cell, vol 90:, 739-751 . He Z. (2000). Crossed wires : L1 and neuropilin interactions. Neuron, vol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés qui permettent l'identification de modulateurs de réponses immunitaires médiées par des cellules immunitaires efficaces, en particulier de l'amorçage de réponses immunitaires primaires, ainsi que de méthodes de traitement et/ou de prévention des maladies ou d'états pathologiques associés à ou contrôlés par lesdites réponses immunitaires. De manière plus spécifique, l'invention concerne des méthodes d'identification de composés qui modulent l'interaction sélective entre des cellules impliquées dans les réponses immunitaires et/ou qui induisent ou inhibent le recrutement de la sémaphorine par un récepteur de la neuropiline, et qui sont utiles pour moduler les réponses immunitaires médiées par des cellules immunitaires efficaces.
EP02779818A 2001-09-26 2002-09-26 Neuropiline comme nouvelle cible therapeutique pour la modulation de reponses immunitaires Withdrawn EP1429801A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02779818A EP1429801A1 (fr) 2001-09-26 2002-09-26 Neuropiline comme nouvelle cible therapeutique pour la modulation de reponses immunitaires

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01402474 2001-09-26
EP01402474 2001-09-26
EP02779818A EP1429801A1 (fr) 2001-09-26 2002-09-26 Neuropiline comme nouvelle cible therapeutique pour la modulation de reponses immunitaires
PCT/IB2002/004596 WO2003035100A1 (fr) 2001-09-26 2002-09-26 Neuropiline comme nouvelle cible therapeutique pour la modulation de reponses immunitaires

Publications (1)

Publication Number Publication Date
EP1429801A1 true EP1429801A1 (fr) 2004-06-23

Family

ID=8182894

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02779818A Withdrawn EP1429801A1 (fr) 2001-09-26 2002-09-26 Neuropiline comme nouvelle cible therapeutique pour la modulation de reponses immunitaires

Country Status (2)

Country Link
EP (1) EP1429801A1 (fr)
WO (1) WO2003035100A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2297953B1 (es) * 2003-06-30 2009-10-21 Progenika Biopharma, S.A. Metodos in vitro para la deteccion de un carcinoma, determinacion de su estadio o severidad y para la determinacion de su desarrollo.
EP1640717A1 (fr) * 2004-09-28 2006-03-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Procédé et kits pour la identification in vitro de cellules, en particulier de cellules lymphoides, capables d'interagir avec des cellules cibles et leurs applications biologiques
JP2010154842A (ja) * 2008-12-03 2010-07-15 Koji Kawakami Ｅｇｆｒを標的にした新規抗がんキメラペプチド
IT1400024B1 (it) * 2010-05-21 2013-05-17 Uni Politecnica Delle Marche Uso farmaceutico di semaforine.
SG186983A1 (en) * 2010-07-09 2013-02-28 Genentech Inc Anti-neuropilin antibodies and methods of use
EP2522341A1 (fr) 2011-05-13 2012-11-14 Tragex Pharma Compositions pharmaceutiques comportant des inhibiteurs de la neuropiline et leur utilisation dans la prévention et/ou le traitement des troubles angiogènes et des cancers
EP2903692B1 (fr) 2012-10-08 2019-12-25 St. Jude Children's Research Hospital Thérapies fondées sur la régulation de la stabilité et de la fonction des lymphocytes t régulateurs par l'intermédiaire d'un axe neuropiline-1:sémaphorine
KR101510742B1 (ko) * 2013-05-13 2015-04-10 (주)케어젠 비만세포―특이적 아팝토시스-유도용 펩타이드 및 이의 용도
EP2823816A1 (fr) 2013-07-09 2015-01-14 Tragex Pharma Inhibiteur de la neuropiline et son utilisation pour le traitement des maladies liées à la neuropiline
EP3189074B1 (fr) * 2014-09-05 2021-01-13 RSEM, Limited Partnership Compositions et méthodes pour traiter et prévenir l'inflammation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639856A (en) * 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US6428965B1 (en) * 1997-07-17 2002-08-06 The Johns Hopkins University Screening assays for the interaction of semaphorins and neuropilins
CA2313348A1 (fr) * 1997-12-09 1999-06-17 Children's Medical Center Corporation Inhibiteurs solubles du facteur de croissance de l'endothelium vasculaire et leurs utilisations
EP1037925A2 (fr) * 1997-12-09 2000-09-27 Children's Medical Center Corporation Fonction et utilisation de l'antagoniste du recepteur de la neuropiline
AU7073800A (en) * 1999-08-25 2001-03-19 Regents Of The University Of California, The Novel plexins and uses thereof
WO2001017559A1 (fr) * 1999-09-08 2001-03-15 Immunex Corporation Modulation par semaphorines de la migration des cellules immunitaires
WO2001018044A2 (fr) * 1999-09-08 2001-03-15 Immunex Corporation Modulation par semaphorines de l'efflux cellulaire

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO03035100A1 *

Also Published As

Publication number Publication date
WO2003035100A1 (fr) 2003-05-01

Similar Documents

Publication Publication Date Title
US20130101605A1 (en) Modulators and modulation of the interaction between rgm and neogenin
KR101106441B1 (ko) 노고 수용체 결합 단백질
US20060199195A1 (en) Nucleic acid encoding Schwannomin-Binding-Proteins and products related thereto
JP2003259887A (ja) カドヘリン物質および方法
WO2003035100A1 (fr) Neuropiline comme nouvelle cible therapeutique pour la modulation de reponses immunitaires
JP2002515444A (ja) 骨粗鬆症の治療方法
CA2245956A1 (fr) Anticorps monoclonaux specifiques des cadherines de cellules endotheliales et leurs utilisations
JP3771218B2 (ja) 細胞老化関連核酸配列及びタンパク質
CN100352832C (zh) 促进毛发生长的寡肽
WO2008112201A2 (fr) Récepteur d'acide lysophosphatidique ciblant une maladie pulmonaire
WO2006133128A2 (fr) Inhibition d'epac, de phospholipase c$g(e), et de phospholipase d en vue de traiter la douleur
US6846636B1 (en) Methods and compositions for HDL holoparticle uptake receptor
Bi et al. Identification of nucleolin as a lipid-raft-dependent β1-integrin-interacting protein in A375 cell migration
US20020045591A1 (en) Methods and therapeutic compositions for treating cancer
JP2001506847A (ja) 結合接着分子（ｊａｍ）、密着結合の膜貫通蛋白質
WO2003100041A1 (fr) Role de la semaphorine cd100 dans la myelinisation
US6248326B1 (en) Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor
JP2004244411A (ja) ガレクチン９含有医薬
WO2001088191A1 (fr) Un nouvel inhibiteur specifique de l'inhibiteur p21waf1cip1
EP2843048A1 (fr) NOUVEAU LIGAND DE L'INTÉGRINE alpha9beta1 ET SES UTILISATIONS
WO1993009808A1 (fr) PROCEDES PERMETTANT DE DETECTER ET D'ISOLER L'uPA-R ET D'INHIBER LA LIAISON DE L'uPA A L'uPA-R
MXPA01009491A (es) Moleculas de acido desoxirribonucleico (adn) que codifican para proteinas clax humanas y sus proteinas de fusion solubles.
US20050226873A1 (en) Medical devices and methods for modulating cell adhesion
Garceau et al. Characterization of cytohesin-1 monoclonal antibodies: expression in neutrophils and during granulocytic maturation of HL-60 cells
Dubiel et al. Intracellular IL-1 Receptor Antagonist Type

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040408

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HERMINE, OLIVIER

Inventor name: ROMEO, PAUL-HENRI

Inventor name: M. LEPELLETIER, YVES

Inventor name: TORDJMAN, RAFAELE

17Q First examination report despatched

Effective date: 20061114

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070325